Ketorolac and (-)-Epicatechin change retinal GFAP and NRF2 expression on hyperglycemic CD1 mice

Our objective was to determine whether (-)-Epicatechin administered alone or simultaneously with topical Ketorolac decreased the relative expression of GFAP and modulated the response of Nrf2 in a mouse model with induced hyperglycemia. We found that GFAP and Nrf2 decreased in the groups that received treatments alone or simultaneous during 8  weeks; even when the effect on the Nrf2 was not pronounced, it showed a higher concentration when GFAP decreased. Our results suggest a protective effect of Ketorolac and (-) - Epicatechin, which seem to limit the preclinical retinal damage caused by inflammation in hyperglycemia.

Source: Journal of Neuroimmunology - January 12, 2023 Category: Allergy & Immunology Authors: Selma Alin Somilleda-Ventura, Ruth Mery L ópez-Mayorga, Eduardo Meaney-Mendiolea, Angel Ivan Orlando Rubio-Gayosso, Héctor Javier Pérez-Cano, Guillermo Manuel Ceballos-Reyes, Virgilio Lima-Gómez Source Type: research